Business
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of
About this update from Codexis, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background, and viewpoints,” said Byron Dorgan, Chair of the Board of Codexis. “In particular, her experience advising publicly traded pharmaceutical and genomic therapy companies will be valuable as we continue focusing efforts on programs where we have the greatest potential to create significant value over the next few years.” “I am excited to leverage my insights in support of Codexis’ impressive portfolio of assets and exceptional enzyme engineering capabilities,” said Ms. Parker. “I look forward to working closely with the talented team in place as we focus on high potential development programs for long-term growth.” Ms. Parker previously served as the Chief Executive Officer, strategic advisor, and a member of the board of directors of the Infectious Disease Research Institute (IDRI), a nonprofit research organization focused on the development of products for the diagnosis, prevention, and treatment of neglected diseases. Prior to IDRI, Ms. Parker managed the formation of Targeted Genetics Corporation as a wholly owned subsidiary of Immunex Corporation, and served as its President and Chief Executive Officer and as a Director from its spinout from Immunex Corporation. She has also served in various capacities at Immunex Corporation, most recently as Vice President, Corporate Development. Since 2014, Ms. Parker has served on the Board of Directors of IMPEL Pharmaceuticals Inc., a publicly traded pharmaceutical company and Sangamo Therapeutics, Inc., a publicly traded genomic therapies company. Ms. Parker also currently serves on the Board of Directors of private gene therapy company StrideBio, Inc. Previously, Ms. Parker served on the board of directors of publicly traded pharmaceutical companies Achieve Life Sciences, Inc., and Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.), as well as on the Board of Directors and the Execut...